Integrated Diagnostics Holdings (LSE:IDHC) EBIT: $9.64 Mil (TTM As of Mar. 2026)


LSE:IDHC Integrated Diagnostics Holdings PLC LSE:IDHC
58 GF Score
Price $0.50
GF Value $0.57
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Integrated Diagnostics Holdings EBIT?

Integrated Diagnostics Holdings LSE:IDHC +0.40% 58 EBIT is $9.64 Mil as of Mar. 2026. GuruFocus rates LSE:IDHC with a GF Score™ of 58/100 and a GF Value™ of $0.57 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Integrated Diagnostics Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $9.64 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $9.64 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Integrated Diagnostics Holdings's annualized ROC % for the quarter that ended in Mar. 2026 was 30.01%. Integrated Diagnostics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 65.64%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Integrated Diagnostics Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.24%.

Integrated Diagnostics Holdings  (LSE:IDHC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Integrated Diagnostics Holdings's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=38.556 * ( 1 - 0% )/( (128.479 + 0)/ 1 )
=38.556/128.479
=30.01 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=180.898 - 26.022 - ( 44.725 - max(0, 56.774 - 83.171+44.725))
=128.479

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Integrated Diagnostics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=38.556/( ( (58.737 + max(-15.499, 0)) + (0 + max(0, 0)) )/ 1 )
=38.556/( ( 58.737 + 0 )/ 1 )
=38.556/58.737
=65.64 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(20.972 + 8.933 + 2.558) - (26.022 + 0 + 21.94)
=-15.499

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Integrated Diagnostics Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=9.639/297.240
=3.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integrated Diagnostics Holdings EBIT Related Terms

Integrated Diagnostics Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Integrated Diagnostics Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integrated Diagnostics Holdings EBIT Chart

Integrated Diagnostics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 148.33 39.63 28.44 31.84 48.98

Integrated Diagnostics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.70 0.00 7.22 0.00 9.64

LSE:IDHC vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integrated Diagnostics Holdings EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Integrated Diagnostics Holdings's EV-to-EBIT falls into.


LSE:IDHC
58GF Score
Integrated Diagnostics Holdings PLC LSE:IDHC
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integrated Diagnostics Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $9.64 Mil mean?
Integrated Diagnostics Holdings (LSE:IDHC) has a EBIT of $9.64 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Integrated Diagnostics Holdings.
Is Integrated Diagnostics Holdings' EBIT too high?
Integrated Diagnostics Holdings' current EBIT is $9.64 Mil. Overall, Integrated Diagnostics Holdings has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' EBIT compare to TMO and DHR?
Integrated Diagnostics Holdings' EBIT of $9.64 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Integrated Diagnostics Holdings. Integrated Diagnostics Holdings's current EBIT is $9.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.57, compared to a current price of $0.50 — trading 11.9% below its estimated fair value. The current EBIT is $9.64 Mil. Integrated Diagnostics Holdings' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current EBIT is $9.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?

Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued. The current stock price of $0.50 is trading 11.9% below its estimated GF Value™ of $0.57. GuruFocus considers Integrated Diagnostics Holdings to be Modestly Undervalued.

Key valuation signals for LSE:IDHC:

  • EBIT: $9.64 Mil
  • GF Value™: $0.57 vs. price of $0.50 (11.9% below fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integrated Diagnostics Holdings Business Description

Address 12 Castle Street, St Helier, JEY, JE2 3RT
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score

Get the complete analysis for LSE:IDHC

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.50
Price
$0.57
GF Value